Abstract: The present invention relates to the field of poly-and oligosaccharides and their dietary effects. In particular it relates to a method of producing a branched ?-glucan. Further aspects of the invention are a branched ?-glucancomprising alternating ?(1?4) and ?(1?6) glucosidic linkages and having ?(1?4,6) branching points, a food composition, and the use of an ?-glucano-transferase enzyme for reducing the digestible carbohydrates of a starch containing food material.

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(?2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds Fc?RIIA or Fc?RIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Abstract: The invention provides multimers of S. solfataricus ssDNA binding protein that bind single stranded DNA. The multimers are robust and stable reagents for use in PCR and other techniques for engineering DNA. The invention further provides methods for performing nucleic acid amplification and engineering using the multimers.

Abstract: This invention provides an HbA1c dehydrogenase that is capable of directly acting on hemoglobin A1c and is less likely to be influenced by oxygen concentration and a method for measurement and a kit of assay reagents using such HbA1c dehydrogenase. The HbA1c dehydrogenase having dehydrogenase activity and capable of directly acting on HbA1c is obtained by substitution of one or more amino acid residues at positions corresponding to positions 280, 269, 54, 241, and 267 of the amadoriase that is capable of directly acting on hemoglobin A1c and is derived from, for example, the genus Coniochaeta. This invention also provides a method for measurement of HbA1c, a kit of assay reagents, and a sensor using such HbA1c dehydrogenase. Such HbA1c dehydrogenase is capable of directly acting on hemoglobin A1c and has lowered oxidase activity and/or enhanced dehydrogenase activity.

Abstract: A biosensor system, method and apparatus are provided for implementing threshold based correction functions for biosensors. A primary measurement of an analyte value is obtained. A secondary measurement of a secondary effect is obtained and is compared with a threshold value. A correction function is identified responsive to the compared values. The correction function is applied to the primary measurement of the analyte value to provide a corrected analyte value. The correction method uses correction curves that are provided to correct for an interference effect. The correction curves can be linear or non-linear. The correction method provides different correction functions above and below the threshold value. The correction functions may be dependent or independent of the primary measurement that is being corrected. The correction functions may be either linear or nonlinear.

Abstract: The present disclosure relates to a method for obtaining rRNA sequence information, comprising the steps of calling an rDNA sequence from full-length genomic DNA sequence information, assembling the rDNA to form rDNA contigs; and extracting DNA sequence of 16S rRNA having high completeness from the rDNA contigs and correcting an assembly error, and a method for identifying a microorganism, using the rDNA information.

Abstract: Provided are a method for predicting the effect of Daikenchuto, a method for determining the dosage of Daikenchuto, etc.

Abstract: Provided is a compound having the structure: (SIG)-(SI-MOD)m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Abstract: A method of indicating the presence of a bacterial infection in a biological sample is provided. The method detects a marker for infection by providing a device, the device including a biosensor, an interaction arising between the biosensor and the marker when the marker is present in the biological sample. Contacting at least a part of the biological sample with the biosensor of the device, therefore, provides analysis of the biological sample with respect to the marker by detecting for the interaction between the biosensor and the marker. A preferred marker is the enzyme amylase.

Abstract: A method of simultaneously analyzing RNA and DNA in a sample, the method comprising the step (a) contacting the sample with a reverse primer from a first primer pair directed to a target RNA region to effect reverse transcription of RNA into cDNA with a reverse transcriptase; (b) subsequently contacting the sample with (i) a forward primer from the first primer pair directed to a second cDNA region, (ii) a forward and a reverse primers from a second primer pair targeted to a DNA region, and (ii) a DNA polymerase to simultaneously amplify the target cDNA and target DNA region; and (c) analyzing the amplified target cDNA region and/or amplified target DNA region. Also encompassed are uses of the method to analyze gene expression and mutations, kits comprising primers, enzymes, buffers.

Abstract: The present invention discloses a high-throughput and rapid nucleic acids detection method based on capillary microarrays, and belongs to the technical field of biomedicine.

Abstract: A method of preparing a sample may include depositing an aqueous solution comprising copies of a primer into a layer of hydrophobic liquid on a substrate with a thermal inkjet device. A sample may include: a substrate; a layer of hydrophobic liquid on the substrate, the layer of hydrophobic liquid comprising a plurality of droplets of aqueous solution distributed in the layer, wherein the plurality of droplets contain: primers; a polymerase enzyme; deoxynucleotide triphosphates (dNTPs); and a target sequence for replication; and a cover, the cover contacting and covering the layer of hydrophobic liquid.

Abstract: A method for detecting and characterising a microorganism in a clinical sample includes introducing a clinical sample to a first culture vessel and then simultaneously transporting and incubating the clinical sample in a thermally insulated compartment of a sealable container. A test aliquot is removed from the sample and the remainder of the sample is cultured further. The method further includes removing DNA from said test aliquot and performing nucleic acid tests on said DNA to identify the microorganism and to detect the presence or absence of one or more genetic antimicrobial resistance markers in said microorganism.

Abstract: A method of determining absolute quantity of a sample template is provided, comprising: i) providing a series of control templates, each having a different and known copy number; ii) amplifying each control template and the sample template by PCR and detecting a signal correlating to an amount of PCR product in each PCR cycle during an exponential phase to thereby obtain a series of control signals and a sample signal; iii) making a standard curve relating a known copy number of each control template with an intensity of each corresponding control signal for the each PCR cycle; and iv) determining a copy number of the sample template by using the standard curve to translate an intensity of the sample signal to the copy number of the sample template.

Abstract: Disclosed herein are methods and systems for correcting errors in sample amplification, including the errors occurred in determining the number of targets in samples. In some embodiments, the method comprises: stochastically barcoding a plurality of targets in the samples using oligonucleotides comprising stochastic barcodes to generate stochastically barcoded targets; contacting one or more defined barcoded primers with each of the one or more samples; and determining an amplification noise.

Abstract: A primer set includes a terminal primer A including, in its 3?-terminal part, a nucleotide sequence that hybridizes to a 3?-terminal part of a complementary sequence of a first target nucleic acid sequence, a k-th double-headed primer including two polynucleotides linked at their 5? terminal sides, wherein one of the two polynucleotides includes, in its 3?-terminal part, a nucleotide sequence that hybridizes to a 3?-terminal part of a nucleotide sequence of a k-th target nucleic acid, and the other polynucleotide includes, in its 3?-terminal part, a nucleotide sequence that hybridizes to a 3?-terminal part of a complementary sequence of a (k+1)th target nucleic acid, and a terminal primer B including, in its 3?-terminal part, a nucleotide sequence that hybridizes to a 3?-terminal part of a nucleotide sequence of a N-th target nucleic acid.

Abstract: The specification relates generally to methods of detecting, diagnosing, and/or identifying pathogens, e.g., infectious disease pathogens and determining their drug sensitivity and appropriate methods of treatment. This invention also relates generally to methods of monitoring pathogen infection in individual subjects as well as larger populations of subjects.

Abstract: The present disclosure relates to method for detecting P. acnes as well as a method for detecting mutation in genomic sequence of 23S rRNA sequence of P. acnes, particularly mutation A2058G. The method comprises amplifying a region of 23S rRNA specific for P. acnes using primers of SEQ ID Nos. 1 and 2 followed by detecting the mutation through selective action of an endonuclease- at a mismatch at the site of said mutation or post-hybridization with specific P. acnes 23S regions followed by mismatch specific endonuclease action. The presence of A2058G mutation confers antibiotic resistance, particularly clindamycin and erythromycin resistance, and thus the present disclosure also relates to methods of treating acne caused by clindamycin resistant P. acnes by using fluoroquinolone based antibiotics.

Abstract: Differential expression of long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) are used to monitor diseases and determine therapeutic efficacy in, for example, neurological diseases, inflammatory diseases, rheumatic diseases, and autoimmune diseases. Machine learning systems are used to identify lncRNAs or eRNAs having differential expression correlated with responsiveness to various therapies.

Abstract: The invention relates to nucleotide sequence detection based on upconversion nanoprobes and quenching nanoprobes in a sandwich assay.

Abstract: According to the present teachings, methods and compositions are provided that utilize at least one reference dye of formula (I): In some embodiments, a method comprises measuring a detection signal of a reporter dye and at least one reference dye of formula (I). In some embodiments, a composition comprises a reference dye of formula (1), a buffer, a selection of nucleotides and a protein.

Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.

Abstract: Described herein are novel devices and methods for the optical detection of oligonucleotide binding events for diagnostic, point-of-care, drug screening, and theranostic applications, for example, a robust and customizable system to detect specific DNA and RNA oligonucleotides using a carbon nanotube optical signal.

Abstract: Methods, kits, and systems for fixation of RNA permitting its detection in intact tissue, such as, large volume of mammalian tissue are disclosed. The methods, kits, and systems utilize carbodiimide-based chemistry to stably retain RNAs in tissue clarified using CLARITY. Also provided herein are methods, kits, and systems for detection of RNAs in clarified tissue.

Abstract: Methods of, and compositions for, analysis using digital amplification assays with unconventional/inverse changes in photoluminescence to indicate the presence of one or more targets. In an exemplary method, isolated volumes may be formed, only a subset of which contain a target. Each volume may include a probe having a label, a sink having a quencher and configured to hybridize with the probe to quench the label, and a separator configured to hybridize with the probe and/or the sink to block hybridization of the sink with the probe. An amplification reaction may be performed in the volumes to generate an amplicon corresponding to the target. The separator may hybridize with the amplicon, and may be extended or degraded by the amplification reaction. Photoluminescence of the label may be detected from the volumes, and the photoluminescence of target-positive volumes may be less than that of target-negative volumes.

Abstract: A fluorescent dye and quencher mixture for reporting on nucleic acid amplification from a sample includes a fluorescent intercalating dye, a dye sequestering or quenching agent such as hydroxynapthol blue (HNB) or caffeine, and primers, dNTPs, and a nucleic acid polymerizing enzyme or fragment thereof. The presence of the dye in combination with the dye sequestering or quenching agent improves the overall dynamic range of the fluorescent signal as well as shortens the time needed for visualization or image capture of amplified nucleic acid. The fluorescent dye and quencher mixture also enables the detection of nucleic acids in samples having low copy numbers.

Abstract: In some embodiments, provided are methods for nucleic acid amplification include subjecting the nucleic acid to be amplified to partially denaturing conditions. In some embodiments, methods for nucleic acid amplification include amplifying without fully denaturing the nucleic acid that is amplified. In some embodiments, the methods for nucleic acid amplification employ an enzyme that catalyzes homologous recombination and a polymerase. In some embodiments, methods for nucleic acid amplification can be conducted in a single reaction vessel. In some embodiments, methods for nucleic acid amplification can be conducted in a single continuous liquid phase of a reaction mixture, without need for compartmentalization of the reaction mixture or immobilization of reaction components. In some embodiments, methods for nucleic acid amplification comprise a amplifying at least one polynucleotide onto a surface under isothermal amplification conditions, optionally in the presence of a polymer.

Abstract: This disclosure relates to novel detergents for use in various procedures including, for example, nucleic acid amplification reactions such as polymerase chain reaction (PCR). Methods for preparing the modified detergents are also described.

Abstract: Method and apparatus to facilitate separation of solution-phase components surrounding an immobilized multicomponent complex while stabilizing association of the components within the complex. The technique can be used for reducing background signal arising from the presence of non-complexed components harboring detectable labels, thereby enhancing signal-to-background ratios and allowing enhanced detection of the multicomponent complex.

Abstract: The present invention concerns preparation of DNA molecules, such as a library, using a stem-loop oligonucleotide. In particular embodiments, the invention employs a single reaction mixture and conditions. In particular, at least part of the inverted palindrome is removed during the preparation of the molecules to facilitate amplification of the molecules. Thus, in specific embodiments, the DNA molecules are suitable for amplification and are not hindered by the presence of the palindrome.

Abstract: The present disclosure provides compositions, methods and systems for quantifying target sequences and identifying target sequence variants.

Abstract: In some aspects, the present disclosure provides methods for identifying sequence variants in a nucleic acid sample. In some embodiments, a method comprises identifying sequence differences between sequencing reads and a reference sequence, and calling a sequence difference that occurs in at least two different circular polynucleotides, such as two circular polynucleotides having different junctions, or two different sheared polynucleotides as the sequence variant. In some aspects, the present disclosure provides compositions and systems useful in the described method.

Abstract: The present invention provides systems, methods, and compositions for performing molecular tests. In particular, the present invention provides methods, compositions and systems for generating target sequence-linked solid supports (e.g., beads) using a solid support linked to a plurality of capture sequences and capture primers composed of a 3? target-specific portion and a 5? capture sequence portion. In certain embodiments, the target sequence linked solid support is used in sequencing methods (e.g., pyrosequencing, zero-mode waveguide type sequencing, nanopore sequencing, etc.) to determine the sequence of the target sequence (e.g., in order to detect the identity of a target nucleic acid in sample).

Abstract: Described herein are engineered alpha-hemolysin subunits having mutated oligomerization domains for assembling into heptameric nanopores in lipid bilayers.

Abstract: Provided herein are methods and compositions for selective amplification of nucleic acids. The compositions include oligonucleotides with sequence features that allow simultaneous, parallel amplification of multiple targets from a mixture of nucleic acids in a single reaction. Methods of using such oligonucleotides to identify individual targets and create libraries of targets from mixtures of nucleic acids are also provided.

Abstract: The principal purpose of the present invention is to provide a novel stress biomarker that makes it possible to conveniently and accurately assess a state of stress. In addition, the present invention provides a diagnosis kit containing a reagent capable of detecting said biomarker, and a diagnosis method that uses said biomarker. It is possible to use mitochondrial DNA included in a biological fluid as the stress biomarker.

Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.

Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.

Abstract: The present disclosure relates to a method for discovering effective bioactive compounds, based on plant developmental biology, and aims to discover a lead bioactive compound for new drugs by repeating screening based on phenotypes of a plant as a marker on the basis of plant developmental biology. To this end, the present disclosure provides a method for discovering effective bioactive compounds, and includes screening candidates for developing a new drug by using unique phenotypes as a marker shown by a plant when it is grown with a specific material.

Abstract: A method for determining a human subject's risk of developing acute kidney injury (AKI) from acute myocardial infarction (AMI) includes: obtaining a blood sample; determining at least two miRNA expression levels therein, which are selected from miR-23a-3p, miR-24-3p, and miR-145-5p expression levels; calculating probability of developing AKI from AMI based on the at least two miRNA expression levels and a logistic regression model; comparing the probability with a predetermined standard; and determining that the human subject is at the risk of developing AKI when the probability is higher than the predetermined standard. A composition may be administered to the human subject for inhibiting development of AKI, if any.

Abstract: The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.

Abstract: The present invention relates to coding of audio signals, and in particular to high frequency reconstruction methods including a frequency domain harmonic transposer. A system and method for generating a high frequency component of a signal from a low frequency component of the signal is described.

Abstract: Disclosed is a detection method for DNA repair-related genes which respond to low-level radiation. This invention provides a detection method for a DNA repair-related gene which responds to low-level radiation, including the steps of (1) breeding AKR/J mice, as a thymus cancer model, and normal ICR mice in a low-dose radiation environment; (2) collecting thymuses from the AKR/J thymus cancer mouse model and the normal ICR mice which have been bred at the step (1); (3) analyzing genes in the thymuses collected at the step (2); (4) detecting, among the genes analyzed at the step (3), a DNA repair-associated gene expressed commonly or differentially in the AKR/J thymus cancer mouse model and the normal ICR mice; and (5) amplifying the gene detected at the step (4) and measuring the expression level thereof.

Abstract: Provided herein are methods for selecting a drug therapy for a patient with cancer, such as colorectal cancer, pancreatic cancer, lung cancer or breast cancer. The method includes determining or measuring the level of RasGRP1 polynucleotide or polypeptide in a sample from the patient. Also provided herein are methods for determining the likelihood of a good prognosis for a patient with cancer. Additionally, provided herein are methods for predicting the likelihood of a negative clinical response to an anti-EGFR therapy in a subject with cancer.

Abstract: The present invention provides a method of determining the presence of a pulmonary tumor in a subject is provided. Also provided is a method of determining the presence of an aggressive pulmonary tumor in a subject. Additionally, a method of determining the risk of manifesting a pulmonary tumor in a subject is provided. Further provided is a method of determining the risk of manifesting an aggressive pulmonary tumor in a subject. A method for predicting the risk of developing or having a pulmonary tumor in a subject is also provided. A method of establishing lung cancer treatment options is additionally provided.

Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.

Abstract: The present invention relates to the field of molecular biology, cell biology, and cancer biology. Specifically, the present invention relates to methods of treating peripheral T-cell lymphoma (“PTCL”) with a famesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the PTCL subtypes and additional characteristics.

Abstract: The present invention relates to the identification of a number of mutational signatures in patients with cancer. The mutational signatures include new base substitution signatures and rearrangement signatures. The signatures were identified by whole genome sequencing of 560 breast cancers and the application of new and existing mathematical methods to the base substitution and rearrangements found in those cancers.

Abstract: The invention provides methods, nucleic acids and kits for detecting colorectal cell proliferative disorders based on underexpression or methylation of a least one gene selected from RASSF2, TFAP2E, SNDI, PCDHGC3, EDNRB, STOM, GLI3, RXFP3, LimK1, GPR73L1, PCDH1O, DOCKIO and MRPS21, and optionally Septin-9.

Abstract: The invention relates to methods for identifying whether an individual has predominantly a power or endurance profile. In particular, it relates to methods for identifying a predisposition to an ability to respond well to high intensity or low-intensity resistance training by identifying the allele present at the locus of one or more of genetic polymorphisms.